



EHTG Satellite Symposium



Registration
required

<https://eveeno.com/219646358>

2nd Edition European Symposium on Tumors with Microsatellite Instability

Thursday, September 18th 2025
Heidelberg, Germany

Final Program





Program Overview

08:30 to 09:00 Symposium Welcoming

09:00 to 09:10 Symposium Opening

09:10 to 10:50 Genetics and Epigenetics of MSI Cancers

(International Journal of Cancer Special Issue Session)  

09:10 to 09:30 **Keynote: Milestones in Hereditary MSI Cancer**

Richard C. Boland, San Diego

09:30 to 09:45 **LTR12C reactivation upon DNMTi and**

HDACi Treatment

Christoph Plass, Heidelberg

09:45 to 09:55 **Q&A**

09:55 to 10:05 **Microsatellite Instability in Gastric Cancers**

Carla Oliveira, Porto

10:05 to 10:15 **A Novel Branch of the RNA Damage Response Drives Resistance in MSI tumors**

Cédric Chaveroux, Lyon

10:15 to 10:25 **MSI and Low-Penetrance Genes**

Noah Helderman, Leiden

10:25 to 10:40 **Q&A**

10:40 to 11:05 Coffee Break

11:05 to 12:35 Tumor Evolution in MSI – A Biological Perspective

11:05 to 11:25 **Keynote: Darwinian Evolution in MSI Cancer Development as a Key for Cancer Prevention**

Matthias Kloor, Heidelberg



Program Overview

11:05 to 12:35 Tumor Evolution in MSI – A Biological Perspective

11:25 to 11:35 Integrative Analysis of Microsatellite Instability in Colorectal Cancer: Selection of Somatic Variants, Pathophysiological and Clinical Implications
Emmanuelle Despras, Paris

11:35 to 11:45 Immunoediting in MSI Tumors
Aysel Ahadova, Heidelberg

11:45 to 11:55 Q&A

11:55 to 12:05 HSP110 T17 Mutation Status Predicts Prognosis and Treatment Response in Patients with Resectable Gastric MSI Adenocarcinoma
Florence Renaud, Paris

12:05 to 12:15 Mismatch Repair-Deficient Crypt Foci: The Hidden Treasure for Cancer Research
Hugo Montémont, Heidelberg

12:15 to 12:25 WRN and its Role in the Genome Integrity of Mismatch Repair-Deficient Cancers
Gabriel Mattos-Rodrigues, Villejuif

12:25 to 12:35 Q&A

12:35 to 13:35 Lunch Break

13:35 to 15:05 The Evolving Landscape of MSI Diagnostics – Precision in Practice

13:35 to 13:55 Keynote: Improving the Diagnosis and Personalized Care of MSI Cancers at the Era of ICK Blockade
Alex Duval, Paris



Program Overview

13:35 to 15:05 The Evolving Landscape of MSI Diagnostics – Precision in Practice

- 13:55 to 14:05 Diagnostics of MSI tumors – State-of-the-Art and New Developments
Albrecht Stenzinger, Heidelberg
- 14:05 to 14:15 POLE and POLD1 mutations in MSI Cancers
Laura Valle, Barcelona
- 14:15 to 14:25 Questions and Answers
- 14:25 to 14:35 Tumor, Liquid Biopsy and Constitutional MSI Testing Using a Simple Amplicon Sequencing Assay
Richard Gallon, Newcastle
- 14:35 to 14:45 Q&A

14:45 to 15:05 Startup Session (Sponsor)

- 14:45 to 14:55 MSInisght, Arnaud Cutivet, France
- 14:55 to 15:05 PAICON, Witali Aswolinskiy, Germany

15:05 to 15:25 Coffee Break

15:25 to 17:05 Future of MSI Immuno- Therapy and Prevention

- 15:25 to 15:40 Keynote: Checkpoint Inhibitors for Metastatic Cancers
Thierry André, Paris
- 15:40 to 15:55 Keynote: Checkpoint Inhibitors in the Neo-Adjuvant Setting
Romain Cohen, Paris
- 15:55 to 16:05 Q&A



Program Overview

15:25 to 17:05 Future of MSI Immuno- Therapy and Prevention

16:05 to 16:15 New Therapeutics for Patients with MSI Cancer
Refractory to Immune Checkpoint Inhibitors –
WRN Inhibitors

Matthieu Roulleaux-Dugage, Villejuif

16:15 to 16:25 New Therapeutics for Patients with MSI Cancer
Refractory to Immune Checkpoint Inhibitors –
Vb6/10 Agonists Inhibitors

Julien Vibert, Villejuif

16:25 to 16:35 Nous-209 Immunotherapy: from Treatment of MSI
CRC to Cancer Intereception in Lynch Syndrome
Patients

Elisa Scarselli, Rome

16:35 to 16:45 Harnessing Synthetic Lethality in MSI Cancer
WRN Dependency, Resistance Mechanisms,
and Therapeutic Opportunities

Gabriele Picco, Cambridge

16:45 to 17:00 Q&A

17:05 to 18:00 Round Table –

Beyond the Breakthroughs: What's Next for MSI?



Speakers Overview



Prof. Dr. med Richard C. Boland
Univeristy of California - San Diego, USA

is a gastroenterologist and Professor of Medicine at the University of California. He is one of the pioneers in the field of microsatellite instability and hereditary colorectal cancers. His work has significantly advanced the understanding of Lynch syndrome, including genetic and epigenetic basis of colorectal cancer. He has served as President of the American Gastroenterological Association and holds several awards for his scientific contributions.

Dr. Laura Valle
IDIBELL - Barcelona, Spain



is Principal Investigator at the Bellvitge Biomedical Research Institute. Her research focuses on identifying genetic causes of hereditary colorectal cancer and novel predisposition genes. She has contributed to the clinical and molecular characterization of different cancer syndromes and has been awarded several prizes for her outstanding research.



Prof. Dr. Christoph Plass
DKFZ - Heidelberg, Germany

is Head of the Division of Cancer Epigenomics, specialized on the role of DNA methylation and chromatin remodeling in cancer. He is a member of the German National Academy of Sciences Leopoldina and serves as Editor-in-Chief of the International Journal of Cancer.





HEIDELBERG
UNIVERSITY
HOSPITAL

Speakers Overview

[illegible]

Register here
<https://eveeno.com/219646358>





HEIDELBERG
UNIVERSITY
HOSPITAL

Speakers Overview

[illegible]

Register here
<https://eveeno.com/219646358>



Speakers Overview

Dr. Carla Oliveira

Ipatimup - Porto, Portugal

is leader of the "Expression Regulation in Cancer" Group. She is a recognized expert in gastric cancer field for her contribution to the improved understanding of CDH1-related diseases and novel genetic causes of hereditary gastrointestinal cancers. She leads the EU-funded PREVENTABLE project on cancer prevention in high-risk individuals and serves as Secretary General of the Executive Committee of European Society of Human Genetics.



Prof. Dr. med Thierry André

AP-HP Sorbonne University - Paris, France

is a Professor of Medicine at Sorbonne University and Head of the Medical Oncology Department at Saint-Antoine Hospital. Prof. André is Principal Investigator of many phase I, II and III clinical trials evaluating treatment of gastrointestinal tumors, such as MOSAIC and NICHE. He is an international expert in MSI colorectal cancer clinical research, whose work significantly contributed to the development of immune checkpoint therapy.



Dr. med Elisa Scarselli

Nouscom - Rome, Italy

is the Chief Scientific Officer and Co-Founder of Nouscom, a biotechnology company leader in the development of neoantigen-based cancer vaccines (NOUS-209). Her work focuses on leveraging viral vectors to elicit anti-tumor immune response aiming to advance personalized immunotherapy and prevention strategies.



Purposes

Fostering collaboration between clinicians and researchers

Sharing recent advances in MSI-related basic, translational and clinical research across tumor types

Exploring the potential creation of a European Consortium for MSI Cancers to coordinate efforts between clinical and research teams in this field

Venue



Culture and Congress Centre Frauenbad Heidelberg
Bergheimer Straße 45, 69115 Heidelberg, Germany



Thursday, September 18th 2025



From 09:00 am to 06:00 pm
Welcoming start at 08:30 am



Registration required
<https://eveeno.com/219646358>



Organising Committee

Hosts



Prof. Dr. med Matthias Kloor
Acting Department Director



Dr. Aysel Ahadova
PI, Junior Group Leader



Prof. Dr. med Alex Duval
Deputy Director



Dr. med Florence Renaud
Deputy Director



Members



Andrea Klingmann
Director's Assistant



Dr. Hugo Montémont
Postdoctoral Researcher



Dr. Sarah Lévesque
Project Manager



Sarah Sevenet-Rodriguez
Event Manager



Sponsors



PAiCON

Partners

